VYNE Therapeutics Inc (NASDAQ: VYNE)’s stock price has gone rise by 10.11 in comparison to its previous close of 1.88, however, the company has experienced a 12.50% increase in its stock price over the last five trading days. globenewswire.com reported 2024-09-12 that BRIDGEWATER, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced positive data from the single ascending dose (“SAD”) portion of its ongoing Phase 1a trial of VYN202. The Phase 1a trial is a two-part, double-blind, placebo-controlled dose-escalation study in healthy volunteers consisting of SAD and multiple ascending dose (“MAD”) components to evaluate the safety, tolerability, pharmacokinetics (“PK”) and pharmacodynamics of VYN202. Findings from the SAD portion of the Phase 1a trial to date are as follows:
Is It Worth Investing in VYNE Therapeutics Inc (NASDAQ: VYNE) Right Now?
The 36-month beta value for VYNE is also noteworthy at 1.41. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VYNE is 12.67M, and at present, short sellers hold a 0.26% of that float. The average trading volume of VYNE on October 02, 2024 was 40.17K shares.
VYNE’s Market Performance
VYNE stock saw an increase of 12.50% in the past week, with a monthly gain of 13.74% and a quarterly increase of 14.36%. The volatility ratio for the week is 6.40%, and the volatility levels for the last 30 days are 6.56% for VYNE Therapeutics Inc (VYNE). The simple moving average for the past 20 days is 11.03% for VYNE’s stock, with a -6.06% simple moving average for the past 200 days.
Analysts’ Opinion of VYNE
Many brokerage firms have already submitted their reports for VYNE stocks, with H.C. Wainwright repeating the rating for VYNE by listing it as a “Buy.” The predicted price for VYNE in the upcoming period, according to H.C. Wainwright is $7 based on the research report published on December 06, 2021 of the previous year 2021.
VYNE Trading at 11.49% from the 50-Day Moving Average
After a stumble in the market that brought VYNE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.80% of loss for the given period.
Volatility was left at 6.56%, however, over the last 30 days, the volatility rate increased by 6.40%, as shares surge +15.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.43% lower at present.
During the last 5 trading sessions, VYNE rose by +12.50%, which changed the moving average for the period of 200-days by -23.33% in comparison to the 20-day moving average, which settled at $1.8800. In addition, VYNE Therapeutics Inc saw -11.16% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VYNE starting from LEPORE PATRICK G, who purchase 13,000 shares at the price of $3.91 back on Nov 15 ’23. After this action, LEPORE PATRICK G now owns 36,472 shares of VYNE Therapeutics Inc, valued at $50,778 using the latest closing price.
Stock Fundamentals for VYNE
Current profitability levels for the company are sitting at:
- -63.46 for the present operating margin
- 1.0 for the gross margin
The net margin for VYNE Therapeutics Inc stands at -58.45. The total capital return value is set at -0.41. Equity return is now at value -60.47, with -49.92 for asset returns.
Based on VYNE Therapeutics Inc (VYNE), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -184.5. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -117.27.
Currently, EBITDA for the company is -29.26 million with net debt to EBITDA at 0.96. When we switch over and look at the enterprise to sales, we see a ratio of 2.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.13.
Conclusion
In summary, VYNE Therapeutics Inc (VYNE) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
